Obesity is a chronic disease driven by complex neurohormonal and behavioral mechanisms that regulate adipocyte mass by impacting appetite, food reward, and ingestive patterns. This review synthesizes evidence from objective, rather than verbal report–based, methodologies examining how bariatric surgery and obesity medicines modify human eating behavior. Roux-en-Y gastric bypass and sleeve gastrectomy consistently reduce total energy intake through sustained reductions in meal size and eating rate, without systematic changes in meal initiation or macronutrient selection. In small cohorts where food choices did shift, alterations were associated with greater weight loss, highlighting interindividual variability. GLP-1-based therapy similarly reduces energy intake and improves appetitive behavior through strengthened gut–brain signaling, whereas naltrexone/bupropion primarily targets central reward circuits. Overall, bariatric surgery leads to reduced intake without altering food choices, suggesting a benefit from eating “less of the same,” whereas equivalent conclusions for obesity medicines remain premature due to limited direct evidence.
Hernández et al. (Fri,) studied this question.